Literature DB >> 9620913

Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.

S Kudoh1, A Azuma, M Yamamoto, T Izumi, M Ando.   

Abstract

Diffuse panbronchiolitis (DPB) is a chronic inflammatory disease of the airways with a high rate of mortality despite treatment with a combination of antibiotics and the use of supportive therapy such as oxygen administration. Low-dose erythromycin therapy (EM) (400 to 600 mg/d) has been found to improve the survival of patients with DPB, and most patients with DPB in Japan have been treated with this erythromycin regime since 1984. The purpose of this study was to evaluate the effects of treatment with erythromycin on the survival rate of patients with DPB in Japan. We compared the survival rates of 498 patients with DPB after dividing them into three groups according to the date of their first medical examination (Group a: 1970-1979, Group b: 1980-1984, Group c: 1985-1990). DPB had been diagnosed in these patients using the criteria of the Ministry of the Health and Welfare Diffuse Lung Disease Committee (MHW-DLDC), which includes chronic productive cough, shortness of breath, presence of roentgenologically smoldering symmetrical granular shadows in the middle and lower lung fields, limitation of airflow without decrease in DLCO, elevated serum cold hemagglutinin titers, and/or narrowing bronchiolus with infiltration of lymphocytes and foamy alveolar macrophages. These patients were registered in the DPB research group of the Ministry of Health and Welfare (MHW). Survival rates were statistically compared using the generalized-Wilcoxon test. The survival rate of Group c was significantly higher than that of Groups a (p < 0.0001) and b (p < 0. 0001). In Group c, eight of 87 patients died; five died in the EM nontreated subgroup (n = 24), and three died in the EM-treated subgroup (n = 63). There was a significant difference in the survival rates between the two subgroups in Group c (p < 0.001). Treatment with EM was associated with a significant improvement in the rate of survival of patients with DPB. The efficacy of EM treatment increased the survival rate of patients with DPB, which was more significant in the older than in the younger patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620913     DOI: 10.1164/ajrccm.157.6.9710075

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  120 in total

1.  Diffuse panbronchiolitis.

Authors:  Sheng-Hsiang Lin; Yu-Shu Liao
Journal:  CMAJ       Date:  2012-03-05       Impact factor: 8.262

Review 2.  Management of severe asthma in children.

Authors:  Andrew Bush; Sejal Saglani
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

3.  Diffuse panbronchiolitis in a 67-year-old Chinese man.

Authors:  Kristof De Smet; Michel De Maeseneer; Bart Ilsen; Johan De Mey
Journal:  Emerg Radiol       Date:  2010-10-24

Review 4.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

Review 5.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

Review 6.  How has research in the last five years changed my clinical practice?

Authors:  A Bush
Journal:  Arch Dis Child       Date:  2005-08       Impact factor: 3.791

7.  Macrolide immunomodulation of chronic respiratory diseases.

Authors:  Daniel P Healy
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

8.  Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells.

Authors:  Kentaro Nagaoka; Katsunori Yanagihara; Yosuke Harada; Koichi Yamada; Yohei Migiyama; Yoshitomo Morinaga; Hiroo Hasegawa; Koichi Izumikawa; Hiroshi Kakeya; Masaharu Nishimura; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  Advantages and drawbacks of long-term macrolide use in the treatment of non-cystic fibrosis bronchiectasis.

Authors:  Li-Chao Fan; Jin-Fu Xu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

10.  Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.

Authors:  Mark H Gotfried; Rose Jung; Chad R Messick; Israel Rubinstein; Kevin W Garey; Keith A Rodvold; Larry H Danziger
Journal:  Curr Ther Res Clin Exp       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.